/head>

News

9 May 2012:OrganOx

OrganOx Completes Series C Funding

24 April 2012:Summit plc

Summit Receives Regulatory Approval to Enter SMT C1100 into a Phase One Clinical Trial

18 April 2012:Summit plc

Company update: Future Board Changes

March 2012:Zyoxel

ZYOXEL ANNOUNCES EXCLUSIVE AGREEMENT TO COMMERCIALIZE LIVERCHIP TECHNOLOGY

March 2012:Oxtex

LBA syndicate helps to close Oxtex in 150,000 pound funding round

February 2012:OrganOx

Transplant breakthrough as livers 'kept alive' outside body giving hope to hundreds

February 2012:Oxford Nanopore Technologies Ltd

Oxford Nanopore introduces DNA 'strand sequencing' on the high-throughput GridION platform and presents MinION, a sequencer the size of a USB memory stick

January 2012:Oxford Cancer Biomarkers

Quintiles Forms New Biomarker Research and Development Company

September 2011:Oxtex Ltd

Oxtex wins Best Emerging Medtech Award

September 2011:Oxtexs Ltd

Oxtexs Limited Appoints Dr Nicholas Edwards

August 2011:Eykona Technologies Ltd

3D Wound Measurement Business Closes Funding Round

July 2011:Oxford Yasa Motors Ltd

YASA Motors Achieves IS09001:2008 Certification

19/07/2011:Oxford Photovoltaics Ltd

MTI leads 650,000 pound funding round in Oxford Photovoltaics Ltd

27/06/2011:Immunotec

Study Results Show Switching from the Tuberculin Skin Test (TST) to an Interferon Gamma Release Assay (IGRA) can Improve Healthcare Worker Test Adherence at a Lower Cost

01/06/2011:Immunotec

Tuberculosis Expert Joins Oxford Immunotec as Senior Scientific Advisor

26/05/2011:Adaptimmune

Adaptimmune announces Opening of Phase I/II Clinical Trial in Multiple Myeloma

15/04/2011: Oxford Catalysts Group PLC

GTL Demonstration Plant Update

29/03/2011: Avacta

Avacta enters Japanese market

16/03/2011: Oxford Nanopore Technologies

Accelrys and Oxford Nanopore Enter Software Partnership for DNA Sequencing Data Analysis

15/03/2011: InhibOx

InhibOx and COSMIC Discoveries Align to Deliver Full Service Drug Discovery Offering:

14/03/2011: Summit Corporation plc

SMT C1100 increases utrophin in DMD patient muscle cells to therapeutically beneficial levels:

You can also browse older news items in the news archive.

To view details and presentations of past events and information of future events please visit our events page.

back to top

Site Information

Institution
University of Oxford
Site
Oxford Spin-out Equity Management